Stay updated with breaking news from Mark Pennesi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.
Key Takeaways
An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindness, an early-stage clinical trial says.
A recent clinical trial, BRILLIANCE demonstrated the safety and efficacy of CRISPR gene editing in treating inherited blindness caused by mutations in the CEP290 gene.
BRILLIANCE trial results showed 11 out of 14 treated participants experienced some improvements in vision and quality of life measures. CRISPR-based therapy